Trial reportClinical pharmacokinetics2011
Population pharmacokinetics and pharmacodynamics of propofol in morbidly obese patients.
Trial report in Clinical pharmacokinetics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00395681 (Population Pharmacokinetics and Pharmacodynamics of Propofol in the Morbidly Obese Patient), which is not on this map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Population Pharmacokinetics and Pharmacodynamics of Propofol in the Morbidly Obese Patient
Who cites it
23 citing papers in PubMed.
- Comparison of Opioid-Free Versions of Total Intravenous Anesthesia and Inhalational Anesthesia in Bariatric Surgery: A Randomized Controlled Trial.Obesity surgery · 2026Trial
- Review
- Weight-Scaled Dose Optimization of Intravenous Anesthetics in Patients with Obesity: General Anesthesia and Procedural Sedation.Drug design, development and therapy · 2026Review
- From pharmacokinetics to precision dosing: optimizing continuous infusion regimens of ciprofol for elderly patients.Frontiers in pharmacology · 2026Article
- Total intravenous-opioid-free anesthesia/analgesia (OFAA) for a morbid obese patient with a body mass index of 99 kg/mJournal of medical case reports · 2025Article
- Impact of Obesity on Hepatic Drug Clearance: What are the Influential Variables?The AAPS journal · 2024Article
- Direct Oral Anticoagulants in Patients with Obesity and Atrial Fibrillation: Position Paper of Italian National Association of Hospital Cardiologists (ANMCO).Journal of clinical medicine · 2021Review
- Drug dosing in the critically ill obese patient-a focus on sedation, analgesia, and delirium.Critical care (London, England) · 2020Review
- Chloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic and Safety Properties.Clinical pharmacokinetics · 2020Review
- The predictive performance of propofol target-controlled infusion during robotic-assisted laparoscopic prostatectomy with COJournal of anesthesia · 2020Article
- Drug Dose Selection in Pediatric Obesity: Available Information for the Most Commonly Prescribed Drugs to Children.Paediatric drugs · 2019Review
- Article
- Clinical Pharmacokinetics and Pharmacodynamics of Propofol.Clinical pharmacokinetics · 2018Review
- Propofol-associated QTc prolongation.Therapeutic advances in drug safety · 2016Article
- Population pharmacokinetic-pharmacodynamic modeling and dosing simulation of propofol maintenance anesthesia in severely obese adolescents.Paediatric anaesthesia · 2015Article
- Review
- Pharmacokinetics and pharmacodynamics of propofol in cancer patients undergoing major lung surgery.Journal of pharmacokinetics and pharmacodynamics · 2015Article
- Nutrition support during extracorporeal membrane oxygenation (ECMO) in adults: a retrospective audit of 86 patients.Intensive care medicine · 2013Article
- An integrated population pharmacokinetic meta-analysis of propofol in morbidly obese and nonobese adults, adolescents, and children.CPT: pharmacometrics & systems pharmacology · 2013Article
- Propofol Clearance in Morbidly Obese Children and Adolescents : Influence of Age and Body Size.Clinical pharmacokinetics · 2012Article
Corrections and comments
- Commented on by
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesIn view of the increasing prevalence of morbidly obese patients, the influence of excessive total bodyweight (TBW) on the pharmacokinetics and pharmacodynamics of propofol was characterized in this study using bispectral index (BIS) values as a pharmacodynamic endpoint.
methodsA population pharmacokinetic and pharmacodynamic model was developed with the nonlinear mixed-effects modelling software NONMEM VI, on the basis of 491 blood samples from 20 morbidly obese patients (TBW range 98-167 kg) and 725 blood samples from 44 lean patients (TBW range 55-98 kg) from previously published studies. In addition, 2246 BIS values from the 20 morbidly obese patients were available for pharmacodynamic analysis.
resultsIn a three-compartment pharmacokinetic model, TBW proved to be the most predictive covariate for clearance from the central compartment (CL) in the 20 morbidly obese patients (CL 2.33 L/min × [TBW/70]^[0.72]). Similar results were obtained when the morbidly obese patients and the 44 lean patients were analysed together (CL 2.22 L/min × [TBW/70]^[0.67]). No covariates were identified for other pharmacokinetic parameters. The depth of anaesthesia in the morbidly obese patients was adequately described by a two-compartment biophase-distribution model with a sigmoid maximum possible effect (E(max)) pharmacodynamic model (concentration at half-maximum effect [EC(50)] 2.12 mg/L) without covariates.
conclusionWe developed a pharmacokinetic and pharmacodynamic model of propofol in morbidly obese patients, in which TBW proved to be the major determinant of clearance, using an allometric function with an exponent of 0.72. For the other pharmacokinetic and pharmacodynamic parameters, no covariates could be identified. Trial registration number (clinicaltrials.gov): NCT00395681.
Indexed as
Identifiers
21973271What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.